Export

EN
FR
Bleomycin
Essential medicine status
Section:
8. Immunomodulators and antineoplastics 8.2. Antineoplastics and supportive medicines 8.2.1. Cytotoxic medicines
ATC codes: L01DC01
EMLc
Indication
Kaposi sarcoma of unspecified primary site ICD11 code: 2C27.Z
INN
Bleomycin
Medicine type
Chemical agent
List type
Complementary (EML)
(EMLc)
Formulations
Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)
EML status history
First added in 1979 (TRS 641)
Changed in 2015 (TRS 994)
Changed in 2019 (TRS 1021)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Tags
Wikipedia
Bleomycin
DrugBank
Bleomycin
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended that the strength of bleomycin powder for injection be expressed in IU and not mg, to reflect dosing protocols.